This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Medical Ethics  • Dermatology, Other  • Alert me on articles by topic

Hywel Williams, MSc,FRCP,PhD

Arch Dermatol. 2002;138:1602-1603.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M
J Am Acad Dermatol. 2002;46:495-504

Question: What is the efficacy and safety of 1% pimecrolimus cream compared with vehicle in children with atopic dermatitis (AD)?

Design: A combined analysis of 2 identical randomized controlled clinical trials (N = 403).

Setting: Children attending specialist dermatology units in the United States.

Study Participants: Children and adolescents aged 1 to 17 years with AD as defined by the United Kingdom Working Party's refinement of Hanifin and Rajka's diagnostic criteria. Those entered into the study had to have at least 5% body surface area involvement and investigators' global assessment (IGA) baseline score of 2 to 3 (mild to moderate AD) . . . [Full Text of this Article]

Comment

Center of Evidence-Based Dermatology, Queen's Medical Centre, Nottingham, England

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

1% Pimecrolimus Cream for Atopic Dermatitis
Eichenfield et al.
Arch Dermatol 2003;139:1369-1370.
FULL TEXT